Lee Hyojin, Dam Duncan Hieu M, Ha Ji Won, Yue Jun, Odom Teri W
Department of Dermatology, Northwestern University , 676 N. St. Clair Street, Chicago, Illinois 60611, United States.
ACS Nano. 2015 Oct 27;9(10):9859-67. doi: 10.1021/acsnano.5b05138. Epub 2015 Sep 3.
This paper describes how gold nanoparticle nanoconstructs can enhance anticancer effects of lysosomal targeting aptamers in breast cancer cells. Nanoconstructs consisting of anti-HER2 aptamer (human epidermal growth factor receptor 2, HApt) densely grafted on gold nanostars (AuNS) first targeted HER2 and then were internalized via HER2-mediated endocytosis. As incubation time increased, the nanoconstruct complexes were found in vesicular structures, starting from early endosomes to lysosomes as visualized by confocal fluorescence and differential interference contrast microscopy. Within the target organelle, lysosomes, HER2 was degraded by enzymes at low pH, which resulted in apoptosis. At specific time points related to the doubling time of the cancer cells, we found that accumulation of HER2-HApt-AuNS complexes in lysosomes, lysosomal activity, and lysosomal degradation of HER2 were positively correlated. Increased HER2 degradation by HApt-AuNS triggered cell death and cell cycle arrest in the G0/G1 phase inhibition of cell proliferation. This work shows how a perceived disadvantage of nanoparticle-based therapeutics-the inability of nanoconstructs to escape from vesicles and thus induce a biological response-can be overcome by both targeting lysosomes and exploiting lysosomal degradation of the biomarkers.
本文描述了金纳米颗粒纳米结构体如何增强溶酶体靶向适配体在乳腺癌细胞中的抗癌作用。由抗HER2适配体(人表皮生长因子受体2,HApt)密集接枝在金纳米星(AuNS)上组成的纳米结构体首先靶向HER2,然后通过HER2介导的内吞作用内化。随着孵育时间的增加,通过共聚焦荧光和微分干涉对比显微镜观察发现,纳米结构体复合物存在于囊泡结构中,从早期内体到溶酶体。在靶细胞器溶酶体内,HER2在低pH值下被酶降解,导致细胞凋亡。在与癌细胞倍增时间相关的特定时间点,我们发现HER2-HApt-AuNS复合物在溶酶体中的积累、溶酶体活性以及HER2的溶酶体降解呈正相关。HApt-AuNS对HER2降解的增加引发细胞死亡和细胞周期停滞在G0/G1期,抑制细胞增殖。这项工作表明,基于纳米颗粒的治疗方法的一个公认缺点——纳米结构体无法从囊泡中逃逸从而诱导生物学反应——可以通过靶向溶酶体和利用生物标志物的溶酶体降解来克服。